✦ LIBER ✦

Optimizing Treatment with Bcr-Abl Tyrosine Kinase Inhibitors in Philadelphia Chromosome—Positive Chronic Myeloid Leukemia: Focus on Dosing Schedules

✍ Scribed by Jabbour, Elias; Cortés, Jorge E.; Kantarjian, Hagop

Book ID: 119936057
Publisher: CIG Media Group, LP.
Year: 2008
Tongue: English
Weight: 138 KB
Volume: 8
Category: Article
ISSN: 1557-9190
DOI: 10.3816/clm.2008.s.002

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of Philadelphia-chromosome-pos

Treatment of Philadelphia-chromosome-positive human leukemia in scid mouse model with herbimycin A, bcr-abl tyrosine kinase activity inhibitor

✍ Yoshio Honma; Yoshinobu Matsuo; Yasuhide Hayashi; Satoshi Omura 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 French ⚖ 731 KB

The molecular basis of the Philadelphia chromosome (Ph') is a structurally altered c-abl (bcr-abl) gene which encodes an abnormally large protein with protein tyrosine kinase activity. Herbimycin A, which effectively reduced intracellular phosphorylation by bcr-abl tyrosine kinase, preferentially in

Selective induction of apoptosis in Phil

Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR–ABL tyrosine kinase, CGP 57148

✍ Dan, Shingo; Naito, Mikihiko; Tsuruo, Takashi 📂 Article 📅 1998 🏛 Nature Publishing Group 🌐 English ⚖ 272 KB

Activity of a Specific Inhibitor of the

Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome

✍ Druker, Brian J.; Sawyers, Charles L.; Kantarjian, Hagop; Resta, Debra J.; Reese 📂 Article 📅 2001 🏛 Massachusetts Medical Society 🌐 English ⚖ 92 KB

BCR-ABL kinase domain mutation analysis

BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet

✍ Soverini, S.; Hochhaus, A.; Nicolini, F. E.; Gruber, F.; Lange, T.; Saglio, G.; 📂 Article 📅 2011 🏛 American Society of Hematology 🌐 English ⚖ 504 KB

Long-term response to imatinib is not af

Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study

✍ Baccarani, Michele; Druker, Brian J.; Branford, Susan; Kim, Dong-Wook; Pane, Fab 📂 Article 📅 2014 🏛 Carden Jennings Publishing 🌐 English ⚖ 340 KB